Telomir says Telomir-Zn restores visual function, retinal structure in AMD preclinical model

• Telomir Pharmaceuticals highlighted a peer-reviewed preclinical study showing Telomir-Zn improved visual function in a zebrafish AMD model.
• Oral dosing for 14 days restored retinal structure, improved visual response, reduced oxidative stress linked to mitochondrial dysfunction.
• Mechanistic work tied effects to lower labile iron, higher intracellular zinc, inhibition of iron-dependent histone demethylases; KDM5B IC50 63 nM.
• Relative telomeric DNA content increased dose-dependently toward healthy profiles; selected aging-linked DNA methylation changes shifted toward normal.
• Clinical development remains centered on oncology; Telomir-Zn is under an FDA-cleared IND for a Phase 1/2 TNBC trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170830PRIMZONEFULLFEED9828486) on September 17, 2026, and is solely responsible for the information contained therein.